UBS Adjusts Price Target on AbbVie to $200 From $195, Maintains Neutral Rating
Cantor Fitzgerald Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $240
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $231
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $205 to $240
AbbVie Analyst Ratings
Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $231
Evercore ISI Adjusts Price Target on AbbVie to $204 From $192
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating
AbbVie Is Maintained at Buy by Citigroup
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $209
AbbVie (ABBV) Gets a Buy From Piper Sandler
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $206
AbbVie: Balanced Outlook Amid EPS Adjustments and Pipeline Uncertainties Warrants Hold Rating
Goldman Sachs Adjusts Price Target on AbbVie to $208 From $200
AbbVie Price Target Raised to $195.00/Share From $185.00 by B of A Securities
AbbVie Analyst Ratings
BofA Securities Initiates AbbVie(ABBV.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), AbbVie (ABBV) and Elevance Health (ELV)
Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.